A federal judge on Thursday blocked Canadian drug maker Apotex Inc. from marketing a less expensive, generic version of the popular blood-thinner Plavix.
In a decision issued Thursday, U.S. District Judge Sidney H. Stein in Manhattan issued a preliminary injunction that stops Apotex from selling its generic version of Plavix, which is co-marketed by drug makers Bristol-Myers Squibb Co. (BMY) and Sanofi-Aventis (SNY).
Apotex launched a generic version of Plavix earlier this month, renewing a 4-year-old patent fight over the drug. The injunction will prevent Apotex from selling the generic until Judge Stein hears the patent infringement case, which is tentatively set for trial in January.
The judge also refused a request by Bristol-Myers and Sanofi to recall the generic Plavix that has already shipped. Earlier this month, an Apotex lawyer said the company had shipped $500 million worth of generic Plavix and had orders for an additional $1.3 billion.
Source: Medical Malpractice
No comments:
Post a Comment